Delfi Diagnostics received approval from the New York State Department of Health to offer its FirstLook Lung blood-based laboratory-developed test for lung cancer screening. The approval allows the cfDNA-based assay to be marketed statewide while the company continues pursuing FDA clearance. Delfi said evidence from a clinical study of nearly 3,000 patients showed FirstLook Lung raised screening rates by nearly threefold, supporting its claim that the test can increase uptake in populations that are currently under-screened. The company described the move as an access-focused step, with testing available across all 50 U.S. states once fully approved. For biotech and medtech stakeholders, the approval adds to momentum for AI-assisted liquid biopsy and underscores state-level pathways that can precede federal authorization for some screening products.